Optimizing Oral Contraceptives: Role of Immediate Release Formulations in Reproductive Health

Abstract

Oral contraceptive drugs are a cornerstone of reproductive healthcare, offering reliable and reversible birth control through hormonal modulation. This comprehensive review delves into the design and development of immediate release (IR) dosage forms for oral contraceptives, focusing on their pharmacological, formulation, and regulatory perspectives. IR tablets, commonly used in both progestin-only pills (POPs) and combined oral contraceptives (COCs), are engineered to ensure rapid disintegration and absorption of active pharmaceutical ingredients, such as ethinylestradiol and levonorgestrel. The review elaborates on key formulation strategies, including the selection of superdisintegrants, solubility and permeability enhancement techniques, and modern excipient technologies that support bioavailability and patient compliance. It discusses the challenges associated with IR formulations, such as strict adherence requirements, fluctuations in plasma hormone levels, and susceptibility to first-pass metabolism. Further emphasis is placed on the impact of manufacturing techniques like direct compression and granulation on dosage performance and quality control. Regulatory frameworks provided by the USFDA, EMA, and CDSCO are explored, with attention to bioequivalence, dissolution testing, and pharmacovigilance. The role of in vitro-in vivo correlation (IVIVC) is also addressed, highlighting its relevance in bridging laboratory findings with clinical efficacy. The review concludes by identifying opportunities for innovation in formulation science to enhance the safety, effectiveness, and accessibility of IR oral contraceptives, ultimately supporting better reproductive health outcomes globally.

Keywords

Introduction

Advantages of Using Superdisintegrants in IR Oral Contraceptives

1. Faster Onset of Action: By promoting rapid disintegration, superdisintegrants help achieve quicker drug release, leading to faster therapeutic effects. This is particularly important for oral contraceptives, where immediate bioavailability is necessary for effectiveness (52).
2. Improved Compliance: Tablets that disintegrate quickly are more likely to meet patient expectations for convenience and ease of use, potentially improving patient compliance with contraceptive regimens.
3. Consistency and Reliability: Superdisintegrants contribute to batch-to-batch consistency in tablet disintegration, which ensures uniform drug absorption and enhances the reliability of the therapeutic effects of oral contraceptives.

Challenges and Limitations of Superdisintegrants

1. Overuse and Impact on Tablet Hardness: While superdisintegrants are essential for disintegration, overuse may compromise the mechanical strength of the tablet, leading to issues such as fragility or difficulty in handling (53).
2. Potential for Inconsistent Disintegration: In some cases, superdisintegrants may not perform consistently across different batches or formulations, leading to variations in the onset of drug release (54).
3. Limited Knowledge of Long-Term Effects: While superdisintegrants are generally regarded as safe, their long-term effects when used in combination with other excipients and active ingredients in oral contraceptives are not always well understood. Further studies are needed to assess any potential interactions.

4.4 Role of Solubility and Permeability Enhancement Techniques

The bioavailability of oral contraceptive drugs is significantly influenced by their solubility and permeability. For oral contraceptives to be effective, they must rapidly dissolve in the gastrointestinal tract and cross the intestinal membranes to reach systemic circulation. This section explores the role of solubility and permeability enhancement techniques in the formulation of immediate release (IR) oral contraceptive drugs, focusing on their importance in ensuring rapid drug absorption and therapeutic efficacy.

Solubility Enhancement Techniques

Many active pharmaceutical ingredients (APIs) in oral contraceptives suffer from poor water solubility, which can limit their absorption and reduce bioavailability. The solubility of the drug directly impacts the rate of dissolution and, consequently, the onset of action. To address this challenge, various formulation strategies can be employed to enhance the solubility of poorly soluble drugs, ensuring that the API is readily available for absorption in the gastrointestinal tract.

1. Solid Dispersions

Solid dispersions are a widely used technique for enhancing the solubility of poorly soluble drugs. In this approach, the drug is dispersed in a carrier matrix, which improves its wettability and dissolution rate. Polymeric carriers like polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) are commonly used for this purpose. Solid dispersions are beneficial for oral contraceptives, as they improve the bioavailability of APIs that are otherwise poorly soluble in water (55).

Example: Ethinyl estradiol, an active ingredient in combined oral contraceptives, has been shown to have enhanced solubility when formulated as a solid dispersion with PVP (56).

2. Salt Formation

The formation of salts is another common technique to enhance the solubility of drugs. Weakly acidic drugs can form salts with alkaline agents to increase solubility. This technique is particularly useful for drugs with poor solubility in their neutral form but enhanced solubility when in salt form. In oral contraceptives, salts like ethinyl estradiol sodium can be utilized to increase solubility and dissolution rate (57).

3. Nanocrystals and Nanoparticles

Nanotechnology offers a promising approach for improving the solubility of poorly soluble drugs. Nanocrystals or nanoparticles of the API can be formulated, increasing the surface area and improving the rate of dissolution. Nanocrystal technology has been shown to be effective for enhancing the bioavailability of lipophilic drugs in oral contraceptives, as the increased surface area promotes faster drug dissolution (58).

4. Cyclodextrins

Cyclodextrins are cyclic oligosaccharides that can form inclusion complexes with poorly soluble drugs, enhancing their solubility. By encapsulating the drug within the hydrophobic cavity of the cyclodextrin, the solubility of the drug in aqueous media is improved. This technique has been applied in oral contraceptive formulations to enhance the solubility of progesterone and ethinyl estradiol (59). 

Permeability Enhancement Techniques

Once a drug is dissolved in the gastrointestinal tract, it must then pass through the intestinal membrane to enter the systemic circulation. However, many drugs, particularly those with low intestinal permeability, face challenges in crossing the intestinal epithelial cells. Therefore, enhancing the permeability of oral contraceptives is crucial for ensuring adequate absorption and therapeutic efficacy.

1. Use of Permeation Enhancers

Permeation enhancers, or absorption enhancers, are substances that temporarily increase the permeability of the gastrointestinal tract to facilitate drug absorption. These enhancers work by altering the tight junctions between intestinal cells or by increasing the fluidity of the cell membranes. Common permeation enhancers used in the formulation of oral contraceptives include:

Chitosan: This biopolymer has been shown to enhance the permeability of lipophilic drugs by interacting with the intestinal mucosa and increasing drug transport (60).

Fatty acids and surfactants: Certain fatty acids (e.g., caprylic acid) and surfactants (e.g., polysorbate 80) are known to enhance drug absorption by disrupting the lipid bilayer of the intestinal membrane, allowing for better drug permeation (61).

2. Lipid-Based Formulations

Lipid-based formulations, such as self-emulsifying drug delivery systems (SEDDS), are an effective approach for improving the intestinal permeability of oral contraceptives. These formulations include lipid excipients that form microemulsions when in contact with water, which can enhance drug solubilization and increase permeability through the intestinal membranes. Lipid-based delivery systems have been used to improve the absorption of hydrophobic drugs in oral contraceptives (62).

3. Prodrug Approaches

Prodrugs are chemically modified versions of the active drug that are designed to enhance intestinal permeability. After absorption, the prodrug is converted into the active form by enzymatic cleavage within the body. Prodrug strategies are effective for oral contraceptives because they can increase permeability and bioavailability while also potentially offering controlled-release benefits (63). Ethinyl estradiol prodrugs, for example, have been studied to improve intestinal permeability and provide sustained drug action.

4. Microneedle Technology

Though still in its early stages for oral formulations, microneedle technology offers a novel approach to increasing drug permeability. Microneedles, which are usually employed in transdermal drug delivery, can also be designed to penetrate the intestinal mucosa, facilitating the absorption of poorly permeable drugs. This technology could revolutionize oral contraceptive delivery in the future by enhancing absorption through the intestinal wall

(64).

Synergy between Solubility and Permeability Enhancements

Both solubility and permeability are critical for the effective absorption of oral contraceptives. While solubility determines how quickly the drug dissolves in the gastrointestinal tract, permeability dictates how efficiently the dissolved drug crosses the intestinal barrier. Therefore, employing both solubility and permeability enhancement strategies in tandem is often necessary for the formulation of highly effective immediate release oral contraceptive tablets. For instance, using a combination of nanocrystals to enhance solubility and lipid-based formulations to increase permeability may offer synergistic benefits, ensuring that the active ingredient in the contraceptive is rapidly dissolved and effectively absorbed by the body.

5. Pharmacokinetic Considerations

5.1 Absorption Profile of Oral Contraceptives

The absorption profile of oral contraceptives plays a crucial role in determining their effectiveness, onset of action, and overall therapeutic efficacy. Pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential considerations when formulating oral contraceptives to ensure they meet the clinical requirements of both efficacy and safety. In this section, we will specifically focus on the absorption profile of immediate release (IR) oral contraceptive formulations. 

Absorption Mechanism and Site

The primary goal of any oral contraceptive is to ensure that the active pharmaceutical ingredient (API) is absorbed efficiently into the bloodstream to exert its desired effects. Upon oral administration, oral contraceptives undergo absorption through the gastrointestinal tract, primarily in the small intestine, due to its large surface area, and the presence of enzymes and transporters that facilitate drug absorption.

Drug Dissolution:

The first step in absorption is the dissolution of the oral contraceptive tablet. In the case of immediate-release (IR) formulations, the drug must dissolve quickly and efficiently in the stomach or upper gastrointestinal tract to ensure rapid absorption. Dissolution depends on various factors such as solubility, particle size, and pH of the drug. Drugs with low solubility or poor dissolution rates may experience delays in absorption and result in suboptimal bioavailability (65).

Absorption in the Small Intestine:

Once the drug dissolves, the active ingredient is absorbed through the intestinal wall into the systemic circulation. Lipophilic drugs, such as ethinyl estradiol, typically follow a passive diffusion mechanism across the epithelial cells lining the small intestine. These drugs must cross the intestinal epithelial cells, which are selectively permeable, to enter the bloodstream (66).

Transporters:

Many drugs, including oral contraceptives, utilize active transport mechanisms involving solute carriers and ATP-binding cassette (ABC) transporters such as P-glycoprotein to enhance absorption (67). In some cases, certain excipients are included in the formulation to facilitate the absorption of poorly soluble or poorly permeable drugs by affecting the transporters in the intestine (68).

First-Pass Metabolism:

After absorption, oral contraceptive drugs often undergo first-pass metabolism in the liver. This phase is essential because it impacts the bioavailability of the active drug. For oral contraceptives, especially those containing estrogen and progestin, the liver metabolizes the active ingredients before they reach systemic circulation. This metabolic process significantly reduces the concentration of active drug that reaches the systemic circulation and can influence the overall therapeutic effect (69).

Ethinyl Estradiol:

As a highly lipophilic molecule, ethinyl estradiol, the estrogen component of combined oral contraceptives, undergoes significant first-pass metabolism in the liver, leading to a reduction in its bioavailability. To compensate for this, the dosage is carefully adjusted to ensure that enough of the active drug reaches the systemic circulation (70). 

Factors Affecting Absorption

The absorption profile of oral contraceptives can be affected by several factors that may vary from patient to patient. These factors must be considered when designing immediaterelease (IR) formulations to optimize their efficacy and safety.

1. Formulation Factors:

Excipients: The choice of excipients and their concentration can impact the dissolution rate and the absorption profile. Superdisintegrants, such as crosslinked polyvinylpyrrolidone (PVP), can improve the disintegration of the tablet, leading to faster dissolution and faster absorption (71). The use of solubilizing agents like polysorbate 80 can also enhance drug solubility and absorption, particularly for lipophilic drugs (72).

Particle Size: The particle size of the active pharmaceutical ingredient can influence the rate of absorption. Smaller particles have a higher surface area, allowing for faster dissolution and more efficient absorption (73).

2. Gastrointestinal Factors:

Gastric pH: The pH of the stomach can affect the solubility of the active drug. For example, drugs that are weakly acidic may have enhanced solubility in a more acidic environment (74). Gastric pH variations, such as those caused by food intake or conditions like gastritis, can alter the dissolution and absorption rates of oral contraceptives.      

Gastric Emptying Time: The rate at which the stomach empties can also influence the absorption of oral contraceptives. A faster gastric emptying lead to quicker delivery of the drug to the small intestine, potentially accelerating absorption (75).

3. Patient-Specific Factors:

Age: The age of the patient can affect the absorption of oral contraceptives. Elderly patients or those with compromised gastrointestinal function may experience slower gastric emptying and altered intestinal permeability, affecting the overall absorption profile (76).

Body Weight and Composition: Body mass index (BMI) and body fat composition can influence the absorption of lipophilic drugs, such as the ethinyl estradiol in combined oral contraceptives. Higher body fat can impact the distribution and absorption of such drugs (77). o Presence of Food: Food can significantly influence the absorption of oral contraceptives. Some drugs may exhibit increased absorption when taken with food, while others may have reduced bioavailability due to interference with the dissolution process (78).

Clinical Implications of Absorption Profile

The absorption profile of immediate-release oral contraceptives has significant clinical implications. Delayed absorption or inconsistent bioavailability can compromise contraceptive effectiveness. If the active drug is not absorbed in a timely manner, or if its plasma concentration falls below the therapeutic threshold, contraceptive efficacy can be compromised, leading to breakthrough bleeding or unintended pregnancies. To mitigate such risks, formulation strategies focus on ensuring rapid dissolution and consistent absorption. This is particularly important for combined oral contraceptives containing ethinyl estradiol and levonorgestrel or other progestins, as fluctuations in their plasma concentrations could impact cycle control and pregnancy prevention (79).

5.2 Bioavailability and First-Pass Metabolism

Bioavailability and first-pass metabolism are two key pharmacokinetic properties that critically influence the effectiveness and clinical outcomes of oral contraceptives. Understanding these factors is essential when developing immediate-release (IR) formulations for oral contraceptives, as they directly affect the systemic exposure of the drug, its therapeutic efficacy, and the overall patient compliance.

Bioavailability of Oral Contraceptives

Bioavailability refers to the fraction of the administered drug that reaches the systemic circulation in its active form and is available to exert a pharmacological effect. The bioavailability of oral contraceptives is largely influenced by several factors including absorption, first-pass metabolism, and the solubility of the active pharmaceutical ingredients (APIs).

1. Solubility and Dissolution: Oral contraceptives typically contain ethinyl estradiol (an estrogen) and a progestin. These compounds must dissolve quickly in the gastrointestinal (GI) tract to ensure efficient absorption. However, drugs with low solubility, such as ethinyl estradiol, may have poor bioavailability, as they require a large quantity of dissolved drug to cross the intestinal membrane. Consequently, solubility-enhancing technologies are often employed in the formulation to ensure sufficient drug absorption and optimal bioavailability (80).
2. Food-Drug Interactions: The bioavailability of oral contraceptives can be affected by the presence of food in the stomach. In some cases, food may enhance absorption by increasing gastric pH and promoting drug dissolution, while in other cases, food may reduce bioavailability by forming complexes with the drug or affecting gastric emptying time. Therefore, bioavailability studies are critical in determining the optimal conditions for drug administration (81).
3. Interpatient Variability: Bioavailability can also vary between individuals due to factors such as age, body weight, genetic differences, and underlying gastrointestinal conditions. For instance, some individuals may have variations in Pglycoprotein transporters, which can impact the absorption of oral contraceptives. This variability underscores the importance of understanding the patient population when designing immediate-release formulations (82).

 First-Pass Metabolism

First-pass metabolism, also known as presystemic metabolism, occurs primarily in the liver and significantly affects the bioavailability of drugs taken orally. After absorption from the gastrointestinal tract, the drug enters the portal circulation and is transported directly to the liver, where it undergoes enzymatic transformation by the cytochrome P450 enzymes. This process can reduce the amount of active drug that enters the systemic circulation, thereby impacting its therapeutic action.

1. Metabolism of Ethinyl Estradiol: One of the most significant examples of first-pass metabolism in oral contraceptives is the metabolism of ethinyl estradiol, the estrogen component in many combined oral contraceptives (COCs). Ethinyl estradiol is extensively metabolized in the liver by enzymes such as CYP3A4 and CYP1A2 before it reaches the systemic circulation. As a result, the bioavailability of ethinyl estradiol can be as low as 40-60% (83). This first-pass effect necessitates the use of a higher dose of ethinyl estradiol in oral contraceptives to ensure adequate systemic exposure to the estrogen component.
2. Progestin Metabolism: Similarly, progestins such as levonorgestrel also undergo first-pass metabolism in the liver, though their metabolism is typically less extensive compared to ethinyl estradiol. The metabolism of progestins involves enzymes like CYP3A4, but their impact on the overall bioavailability of the active drug may be less pronounced (84). However, variations in the metabolism of progestins can affect both pregnancy prevention and cycle control, making bioavailability an important parameter in formulation design.
3. Impact of First-Pass Metabolism on Dosing: The first-pass effect is a key reason why oral contraceptive formulations are designed with specific doses of ethinyl estradiol and progestins to overcome the bioavailability reduction that occurs due to liver metabolism. In some cases, pharmaceutical strategies such as extended-release formulations or altering the excipient composition (e.g., use of solubilizing agents or lipid-based systems) are employed to optimize the bioavailability of oral contraceptives and ensure that sufficient amounts of the active ingredients are absorbed and available to exert their contraceptive effects (85).

Factors Affecting First-Pass Metabolism

The extent of first-pass metabolism and the subsequent bioavailability of oral contraceptives can be influenced by several factors, which include:

1. Enzyme Activity: The activity of cytochrome P450 enzymes can vary between individuals, impacting the rate of first-pass metabolism. Enzyme induction (e.g., by drugs like rifampin) can increase the metabolism of oral contraceptives, while enzyme inhibition (e.g., by grapefruit juice) can decrease metabolism, leading to higher systemic exposure and potentially increasing the risk of adverse effects (86).
2. Liver Function: Individuals with liver dysfunction (such as those with hepatitis or cirrhosis) may have impaired first-pass metabolism, which can result in higher bioavailability of oral contraceptives. This may increase the risk of side effects, and careful dose adjustments may be required in such cases (87).
3. Drug Interactions: The use of other medications can also influence the first-pass metabolism of oral contraceptives. For example, anticonvulsants and antibiotics may induce liver enzymes, potentially lowering the effectiveness of oral contraceptives. Conversely, certain antifungals and antiretroviral agents may inhibit metabolism, leading to higher systemic concentrations of the drug (88).
4. Gender and Age: Gender and age also play roles in the metabolism of drugs. Women may metabolize drugs differently than men, and older adults often experience a decline in hepatic function, which could affect the first-pass effect and alter bioavailability (89).

Clinical Implications

Understanding bioavailability and first-pass metabolism is essential for optimizing the efficacy of oral contraceptives. These pharmacokinetic factors highlight the importance of designing immediate-release formulations that ensure the drug’s effective absorption and bioavailability while accounting for the inevitable first-pass metabolism that reduces systemic concentrations of the active ingredients. Such formulations must aim to balance effective dosing with the potential for side effects, ensuring both contraceptive efficacy and safety.

5.3 Impact of Food and Gastrointestinal pH

The absorption of oral contraceptive drugs can be significantly influenced by various physiological factors, including the presence of food and the pH of the gastrointestinal (GI) tract. These factors are important considerations for the development and efficacy of immediate-release (IR) dosage forms of oral contraceptives. Understanding how food and GI pH affect the pharmacokinetics of oral contraceptives allows for improved formulation design and more effective patient guidance on drug administration.

Impact of Food on the Absorption of Oral Contraceptives

Food intake can affect the dissolution, absorption, and bioavailability of oral contraceptive drugs. While some oral contraceptives may require specific administration instructions (such as with or without food), the overall impact of food varies based on the drug formulation, the type of food, and individual patient factors (90).

1. Food as a Positive Modulator of Absorption: For some oral contraceptives, particularly those with poor solubility, taking the drug with food can enhance its dissolution. Food increases the gastric pH, which may facilitate the dissolution of poorly soluble compounds. It also slows gastric emptying, leading to a prolonged residence time in the stomach, potentially improving drug absorption (91). For example, certain formulations of ethinyl estradiol in combined oral contraceptives (COCs) may benefit from food intake, which enhances the drug’s solubility and absorption (92).
2. Food-Induced Interactions and Reduced Absorption: On the other hand, some foods can negatively influence the absorption of oral contraceptives. High-fat meals can alter the solubility and bioavailability of some active ingredients, either by forming insoluble complexes or by affecting the rate of gastric emptying (93). For instance, studies have shown that grapefruit juice, which inhibits the CYP3A4 enzyme, may increase the plasma concentration of some progestins and ethinyl estradiol, while antacids and certain foods that increase gastric pH can interfere with the absorption of some drug components (94).
3. Variable Food Effects Across Different Drugs: The effect of food on oral contraceptives is not uniform across all drugs or formulations. Progestins, for example, may have a different absorption profile when taken with food, compared to estrogens like ethinyl estradiol. Consequently, clinical guidelines often specify whether oral contraceptives should be taken with food, based on the drug’s pharmacokinetic properties (95).

Impact of Gastrointestinal pH on Oral Contraceptives

The pH of the gastrointestinal tract plays a significant role in the solubility and absorption of oral contraceptive drugs. The gastric pH is highly variable and can fluctuate based on fasting versus fed states, the presence of acid-reducing medications, and individual differences in gastric acid secretion. This variability can influence the bioavailability of oral contraceptives.

1. Influence of Gastric pH on Drug Solubility: Many drugs, including oral contraceptives, have poor solubility at low pH (in the acidic environment of the stomach). When the gastric pH is raised—either due to food intake or through the use of proton pump inhibitors (PPIs) or antacids—the solubility of these drugs may increase, leading to enhanced drug absorption. This effect is particularly relevant for oral contraceptives containing ethinyl estradiol, a compound known to be poorly soluble in highly acidic environments (96).
2. Proton Pump Inhibitors (PPIs): The use of PPIs or H2 receptor antagonists can significantly alter gastric pH, raising it from a normally acidic level of 1.5-3.5 to a higher, more alkaline range (97). This alteration in pH can potentially affect the solubility and absorption of oral contraceptive drugs. For example, a higher gastric pH may reduce the solubility of ethinyl estradiol and other progestins, potentially reducing their bioavailability and effectiveness. This underscores the need for careful consideration when prescribing oral contraceptives to individuals on acid-reducing therapies (98).
3. Gastrointestinal pH and Drug Absorption in Immediate-Release Formulations: In immediate-release formulations, where the drug is designed to be rapidly dissolved and absorbed in the stomach or upper gastrointestinal tract, changes in gastric pH can result in variability in the rate and extent of absorption. Ethinyl estradiol, for instance, may experience reduced bioavailability when the gastric pH is raised in the presence of food or antacid use, which could impact the effectiveness of the contraceptive (99).
4. Individual Variability in GI pH: Individual variations in gastric acid secretion and intestinal transit time further contribute to the variability in drug absorption. Some individuals naturally have a higher gastric pH, which may necessitate dose adjustments in oral contraceptive formulations. This is particularly important for progestin-only pills (POPs) or formulations where consistent bioavailability is crucial for contraceptive effectiveness (100).

6. Evaluation Parameters of Immediate Release Dosage Forms

6.1 Preformulation Studies

Preformulation studies are an essential early phase in the development of immediate release (IR) dosage forms for oral contraceptive drugs. These studies help to characterize the physicochemical properties of the active pharmaceutical ingredients (APIs) and excipients, allowing formulators to design the dosage form that ensures optimal bioavailability and efficacy. Preformulation studies are critical in understanding how different formulation variables, including excipients, processing methods, and environmental conditions, can impact the final product's quality and performance. The goal of preformulation is to determine the appropriate selection and combination of excipients, establish the stability profile, and predict the drug’s dissolution behavior.

 Key Aspects of Preformulation Studies in Oral Contraceptive Dosage Forms

1.Physicochemical Properties of the Active Pharmaceutical Ingredient (API)

The physicochemical properties of the API in oral contraceptives directly influence the selection of excipients, the method of manufacture, and the release profile of the dosage form. These properties include:

• Solubility: The solubility of the active drug in water is one of the most critical properties for immediate-release formulations. Drugs with poor aqueous solubility may exhibit reduced bioavailability and delayed onset of action, which can affect contraceptive efficacy. For example, ethinyl estradiol (a common active ingredient in combined oral contraceptives) has limited solubility in water, and formulation strategies are employed to enhance its solubility and subsequent absorption (101).
• Stability: The chemical stability of the API under different storage conditions is paramount. Preformulation studies determine how the API degrades over time and whether it requires specific conditions (such as refrigeration or protection from light) to maintain its potency. For oral contraceptives, stability testing may also include evaluating the stability of the formulation in solid dosage forms (e.g., tablets) under various environmental conditions like temperature, humidity, and exposure to light (102).
• Melting Point and Polymorphism: The melting point and polymorphic forms of the API affect its solubility and dissolution rate. Polymorphs (different crystalline forms) can have varying dissolution characteristics, which may impact the onset and duration of contraceptive action. Identifying the most suitable polymorph for formulation is part of the preformulation studies (103).

2. Selection of Excipients

Choosing the right excipients is critical to achieving the desired performance of the immediate-release dosage form. Preformulation studies help identify excipients that can:

• Enhance solubility and dissolution: Some excipients, such as solubilizers, surfactants, or complexing agents, are chosen to improve the solubility of poorly soluble drugs like progestins and ethinyl estradiol (104). For example, cyclodextrins may be used to form inclusion complexes with poorly soluble drugs, enhancing their solubility and bioavailability (105).
• Control the release profile: Even though the formulation is intended to be an immediate release, certain excipients like superdisintegrants are used to facilitate rapid disintegration and dissolution of the tablet once ingested, ensuring that the active ingredient is released quickly into the systemic circulation (106).
• Ensure stability: Some excipients act as stabilizers to prevent degradation of the API, ensuring the efficacy of the oral contraceptive throughout its shelf life. Antioxidants, preservatives, and buffering agents may be incorporated into the formulation to maintain the stability of the active drug and prevent hydrolytic degradation or oxidation (107).

3. Dissolution and Release Rate Studies

Dissolution testing is an essential component of preformulation studies, particularly for immediate-release oral contraceptives, where rapid absorption is required to achieve timely contraceptive effects. Dissolution testing helps to assess:

• Dissolution profile: The rate at which the drug dissolves in a given medium simulates the conditions in the gastrointestinal tract. The dissolution profile should meet regulatory requirements and provide the desired bioavailability. For oral contraceptives, it is essential that the active pharmaceutical ingredient dissolves efficiently and rapidly after oral administration (108).
• Comparative dissolution: In cases where there are multiple formulations being tested, preformulation studies include comparative dissolution tests to ensure that the newly developed formulation meets the same or better dissolution characteristics as the marketed product. This is particularly important for the bioequivalence of generic oral contraceptives (109).

4. Stability Testing

Preformulation studies include stability testing to determine how long the oral contraceptive formulation remains stable under various conditions. Stability testing is critical for assessing:

• Shelf-life estimation: Based on the stability data, formulators can estimate the shelf life of the product and determine appropriate storage conditions (e.g., temperature, humidity) to preserve the drug's efficacy and safety.
• Compatibility with excipients: Preformulation studies evaluate potential interactions between the API and excipients, ensuring that no chemical or physical changes occur during storage. Physical changes, such as caking, discoloration, or loss of mechanical strength in tablets, could compromise the effectiveness of the contraceptive and need to be addressed (110).

5. Particle Size and Surface Area

The particle size of the API is an essential factor in determining its dissolution rate and bioavailability. Smaller particle sizes typically lead to a larger surface area, which enhances dissolution rates. During preformulation, the particle size distribution is evaluated to ensure optimal dissolution and absorption profiles. Nanomaterial-based or micronized formulations may be used for poorly soluble active ingredients to enhance their performance (111).

6.2 Dissolution Testing

Dissolution testing is an essential quality control tool used in the development and evaluation of immediate release (IR) dosage forms for oral contraceptive drugs. The dissolution process, which refers to the rate at which a drug dissolves in a given solvent, plays a crucial role in determining the bioavailability, efficacy, and onset of action of the oral contraceptive. Dissolution testing helps predict how the active pharmaceutical ingredient (API) will be absorbed in the gastrointestinal (GI) tract, which is critical for achieving effective and timely contraceptive action.

Importance of Dissolution Testing in Oral Contraceptive Formulations

Dissolution testing is particularly important for oral contraceptive formulations because of the need for rapid and consistent absorption of the active ingredients (such as ethinyl estradiol and progestins) to ensure efficacy in preventing pregnancy. The following points highlight the critical role of dissolution testing in the development of immediate-release oral contraceptives:

1. Predicting Bioavailability

Bioavailability refers to the proportion of the active drug that reaches the systemic circulation after administration. For immediate-release formulations, rapid dissolution and absorption are essential to achieving the desired plasma concentration of the drug in a short time. Dissolution testing serves as a surrogate for in vivo absorption, providing valuable data on how fast the drug will be released and absorbed in the body (112).

• Standardized dissolution tests can simulate conditions in the stomach or intestines, where the drug must rapidly dissolve to enter the bloodstream.
• Dissolution testing helps ensure that oral contraceptives consistently release their active ingredients, ensuring that the drug will be absorbed at the appropriate rate, which is crucial for maintaining contraceptive efficacy.

2. Regulatory Requirement

Dissolution testing is a required in vitro test for regulatory approval by agencies such as the U.S. FDA and the European Medicines Agency (EMA). These regulatory bodies use dissolution profiles to evaluate whether a new oral contraceptive formulation is bioequivalent to the marketed product, ensuring that patients receive the intended therapeutic effect. Regulatory guidelines specify the dissolution specifications, which should match the dissolution profile of the reference product (113).

• Regulatory authorities often require that the dissolution profile of the generic oral contraceptive matches that of the brand-name product to ensure therapeutic equivalence.
• A lack of consistency in the dissolution profiles could result in delays in the approval process or rejection of a product.

3. Predicting Therapeutic Efficacy

The effectiveness of oral contraceptives is directly linked to the consistent release of active ingredients, which must be absorbed in the bloodstream within a specific timeframe. Immediate-release formulations, in particular, require rapid dissolution to ensure the timely onset of action. If a formulation fails to dissolve appropriately, it can lead to fluctuations in plasma drug concentrations, potentially compromising the contraceptive’s efficacy (114).

• For combined oral contraceptives (COCs), which include both an estrogen and a progestin, ensuring a uniform dissolution and absorption pattern is essential for avoiding side effects and ensuring reliable efficacy.
• Similarly, for progestin-only pills, dissolution testing ensures that the progestin is available at the correct concentration to prevent ovulation and promote the desired contraceptive effect.

4. Comparative Dissolution Testing

Comparative dissolution testing is commonly employed in the development of generic oral contraceptives to demonstrate bioequivalence to the reference product. The dissolution profile of a generic formulation is compared to the innovator's product under the same conditions to ensure that both formulations have similar release characteristics. This is a critical step in establishing the generic formulation's therapeutic equivalence to the brandname drug.

• The FDA and other regulatory bodies require that generic formulations show similarity in dissolution profiles to the innovator's product to ensure that patients receive the same therapeutic benefit (115).
• Dissolution testing ensures that the generic drug provides the same rate of drug release, thereby guaranteeing consistent contraceptive efficacy.

Factors Affecting Dissolution Testing in Oral Contraceptives

Several factors must be considered when designing and interpreting dissolution testing for oral contraceptives:

1. Testing Conditions

Dissolution testing is typically conducted using a basket apparatus or paddle method at a defined temperature (usually 37°C to mimic body temperature) and in a medium that simulates the conditions of the gastric fluid (such as pH 1.2 for the stomach). These testing conditions are carefully selected to simulate the physiological environment in which the oral contraceptive will dissolve and be absorbed.

• For immediate-release formulations, the dissolution medium typically has a low pH (simulating stomach conditions) for a specific time, followed by a neutral pH (mimicking the transition to the intestines).
• The stirring rate and medium volume are standardized to ensure consistency in results.

2. Disintegration and Release Profile

Disintegration testing is often conducted alongside dissolution testing to assess how well the tablet or capsule breaks apart in the digestive tract. A rapid disintegration rate helps ensure that the drug particles are released quickly into the dissolution medium, facilitating a quicker absorption of the API (116).

• The release profile must meet specified criteria for drug release rate and extent of dissolution, with a goal to achieve nearly complete dissolution within a specified time period (often 30 minutes or less for immediate-release formulations).
• The dissolution testing results must align with the therapeutic requirements for the oral contraceptive to ensure that the drug’s action begins within the necessary timeframe.

3. Impact of Formulation Variations

Formulation variables such as the type of excipients, the particle size of the API, and the use of superdisintegrants or solubility enhancers can influence the dissolution rate. Preformulation studies and early formulation optimization help determine the best combination of excipients to achieve the desired dissolution characteristics.

• Superdisintegrants, such as sodium starch glycolate or croscaramellose sodium, are often incorporated to enhance the rapid breakdown of the tablet.
• Solubility enhancers such as cyclodextrins or surfactants may be used to improve the dissolution of poorly soluble drugs, such as ethinyl estradiol.

6.3 In Vitro–In Vivo Correlation (IVIVC)

In Vitro-In Vivo Correlation (IVIVC) is an essential concept in the development and evaluation of immediate release (IR) oral contraceptive dosage forms. It refers to the relationship between the dissolution profile of a drug in an in vitro environment and its pharmacokinetic behavior (e.g., absorption and bioavailability) in the human body. IVIVC provides critical insights into how changes in the dissolution characteristics of the dosage form might influence its therapeutic effectiveness. This is particularly important for oral contraceptives, where achieving consistent plasma drug levels is crucial for ensuring contraceptive efficacy.  IVIVC helps in understanding how well the in vitro dissolution tests can predict the in vivo performance of oral contraceptives, especially in terms of their onset, duration of action, and overall effectiveness in preventing pregnancy. Since oral contraceptives typically require rapid onset and stable plasma drug levels, a strong IVIVC is important to confirm that the formulation will behave as expected in the human body.

Importance of IVIVC in Oral Contraceptive Drug Development

The following points highlight the significance of IVIVC in the development and evaluation of immediate-release oral contraceptive drugs:

1. Predicting Bioavailability and Therapeutic Efficacy

IVIVC allows researchers and formulators to predict how well the drug will be absorbed in the body and how quickly it will reach therapeutic levels. Since oral contraceptives need to be absorbed and distributed efficiently, an IVIVC correlation can help ensure that the dosage form achieves adequate plasma concentrations of the active pharmaceutical ingredients (APIs), such as ethinyl estradiol and progestins.

• Bioavailability prediction is a critical aspect of IVIVC, as it helps estimate the amount of active ingredient reaching the systemic circulation and its therapeutic effect. A robust IVIVC ensures the drug’s bioavailability remains consistent, providing reliable contraceptive action.
• It also helps optimize drug release profiles, ensuring the drug’s pharmacokinetics match the desired therapeutic effects (e.g., sustained hormonal levels for the duration of the contraceptive cycle).

2. Reducing the Need for Extensive Clinical Trials

One of the major advantages of developing an IVIVC for oral contraceptives is that it can potentially reduce the need for large and expensive clinical trials. By correlating in vitro dissolution data with in vivo pharmacokinetic data, researchers can predict the bioavailability and efficacy of a new formulation without having to conduct exhaustive human trials. This can shorten development timelines and lower costs while ensuring the safety and effectiveness of the product.

• In vitro dissolution testing becomes a reliable predictor of the clinical performance of oral contraceptives, making it a cost-effective and time-saving method during formulation development (117).

CONCLUSION

Immediate release (IR) dosage forms have played a pivotal role in revolutionizing the administration of oral contraceptive drugs by providing rapid onset of action, enhanced patient compliance, and ease of manufacturing. This review comprehensively examined the pharmacological, technological, and regulatory aspects that govern the successful development and deployment of IR oral contraceptives. By focusing on the optimization of excipients, formulation strategies, and bioavailability enhancement techniques, IR formulations have effectively addressed many of the challenges related to hormonal stability, absorption, and patient adherence. Despite their advantages, IR contraceptives are not without limitations—chief among them being the dependency on strict dosing schedules and the potential variability in plasma hormone levels due to gastrointestinal or metabolic influences. These issues underscore the need for ongoing innovation, such as advanced excipient systems, improved disintegration technologies, and the integration of nanotechnology or permeability enhancers, all aimed at maintaining consistent therapeutic outcomes. Moreover, regulatory agencies worldwide continue to emphasize quality assurance through stringent requirements for dissolution testing, bioequivalence, and post-marketing surveillance. The collective insight from pharmacokinetic modeling, in vitro–in vivo correlation, and patient-centered design approaches provides a robust foundation for future advances. In conclusion, while immediate release oral contraceptives currently represent a highly effective and accessible form of birth control, continued research and technological evolution are essential to further improve their efficacy, safety, and user convenience. These advancements will support broader reproductive health goals and help meet the diverse needs of users worldwide.

REFERENCE

1. Raviele KM. 4. Reproductive Health and the Practice of Gynecology. Catholic Witness in Health Care: Practicing Medicine in Truth and Love. 2017 Sep 15:105.
2. Bachmann G, Korner P. Bleeding patterns associated with non-oral hormonal contraceptives: a review of the literature. Contraception. 2009 Apr 1;79(4):247-58.
3. Barnett C, Hagemann C, Dinger J, Do Minh T, Heinemann K. Fertility and combined oral contraceptives–unintended pregnancies and planned pregnancies following oral contraceptive use–results from the INAS-SCORE study. The European Journal of Contraception & Reproductive Health Care. 2017 Jan 2;22(1):17-23.
4. Burkman RT. Oral contraceptives: current status. Clinical obstetrics and gynecology. 2001 Mar 1;44(1):62-72.
5. Piggott T, Moja L, Huttner B, Okwen P, Raviglione MC, Kredo T, Schünemann HJ. WHO Model list of essential medicines: Visions for the future. Bulletin of the World Health Organization. 2024 Aug 29;102(10):722.
6.  Koren G, Pastuszak A, Ito S. Drugs in pregnancy. New England Journal of Medicine. 1998 Apr 16;338(16):1128-37.
7.  Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharmaceutical research. 1998 Jun; 15:889-96.
8.  Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Reviews in Endocrine and Metabolic Disorders. 2002 Sep; 3:211-24.
9.  Martindale C. The complete drug references. Sweetman SC, editor. London: Pharmaceutical press; 2009 Mar.
10. Coelingh Bennink HJ, van Gennip FA, Gerrits MG, Egberts JF, Gemzell-Danielsson K, Kopp-Kallner H. Health benefits of combined oral contraceptives–a narrative review. The European Journal of Contraception & Reproductive Health Care. 2024 Mar 3;29(2):40-52.
11. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus> 20 µg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews. 2013(8).
12. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs & aging. 2004 Nov; 21:865-83.
13. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. American journal of obstetrics and gynecology. 2001 Aug 1;185(2):S4-12.
14. Speroff L, Darney PD. A clinical guide for contraception. Lippincott Williams & Wilkins; 2011.
15. Raviele KM. 4. Reproductive Health and the Practice of Gynecology. Catholic Witness in Health Care: Practicing Medicine in Truth and Love. 2017 Sep 15:105.
16. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010 Nov 1;82(5):396-403.
17. Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
18. Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, Duan J. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US Food and Drug Administration for new drugs. The AAPS Journal. 2021 Mar; 23:1-4.
19. Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
20. Bruisten SM, Nilsson-Ihrfelt E, Buhrman M, Ekselius L. TOXBASE. Emerg Med J. 2006 Aug; 23 (8): 614-7. PMID: 16858093 [PubMed-in process] 24: Team V, Markovic M. Internet advertising of artificial tanning in Australia. InOncol Nurs Forum 2006 Nov 3 (Vol. 33, No. 2, pp. 249-54).
21. Dinger J, Do Minh T, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large US cohort comparing progestogen and regimen. Obstetrics & Gynecology. 2011 Jan 1;117(1):33-40.
22. Martindale C. The complete drug reference. Sweetman SC, editor. London: Pharmaceutical press; 2009 Mar.
23. Hatcher RA. Contraceptive technology. Ardent Media; 2007.
24. Stanczyk FZ, Archer DF. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception. 2014 Apr 1;89(4):242-52.
25. Kuhnz W, Hümpel M, Biere H, Gross D. Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. European journal of clinical pharmacology. 1996 May; 50:231-5.
26. Goldenberg RL, Das AF, Meis PJ. Maternal±fetal medicine. Acta Obstet Gynecol Scand. 2001; 80:120-5.
27. Trussell J. Contraceptive failure in the United States. Contraception. 2004 Aug 1;70(2):89-96.
28. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clinical pharmacokinetics. 1990 Jun; 18:472-84.
29. French R, Van Vliet H, Cowan F, Mansour D, Morris S, Hughes D, Robinson A, Proctor T, Summerbell C, Logan S, Helmerhorst F. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. The Cochrane database of systematic reviews. 2004;2004(3):CD001776.
30. Kolhe MH, Gilhotra RM, Asane GS. Development of capsule containing immediate release tablet and extended release floating tablet for monitoring release of atenolol. Research Journal of Pharmacy and Technology. 2021;14(4):2216-20.
31. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Philadelphia: Lea & Febiger; 1976.
32. Mahato RI, Narang AS. Pharmaceutical dosage forms and drug delivery: revised and expanded. CRC Press; 2017 Nov 22.
33. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. Journal of pharmaceutical sciences. 1996 Oct;85(10):1017-25.
34. Rowe RC, Sheskey P, Quinn M. Handbook of pharmaceutical excipients. Libros Digitales-Pharmaceutical Press; 2009.
35. Vyas SP, Khar RK. Controlled drug delivery concepts and advances. Vallabh prakashan. 2002; 1:411-7.
36. Kamboj S, Mittal A, Kumawat M. Direct Compression: A Novel Approach to Tablet Formulation. J Pharm Bioallied Sci. 2012;4(1):9–15.
37. Dwivedi J, Sachan P, Wal P, Kosey S, Khan MM. Progressive journey of phytosomes: preparation, characterization, patents, clinical trials & commercial products. J Res Pharm. 2023 Sep 1;27(5):1687-733.
38. Iqubal MK, Singh PK, Shuaib M, Iqubal A, Singh M. Recent advances in direct compression technique for pharmaceutical tablet formulation. Int J Pharm Res & Devel. 2014;6(1):49-57.
39. Basudkar V, Gharat SA, Momin MM, Shringarpure M. A review of anti-aging nanoformulations: Recent developments in excipients for nanocosmeceuticals and regulatory guidelines. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2022;39(3).
40. Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.
41. Bansal AK, Choi J, Simonelli AP. Granulation Techniques: Wet Granulation. In: Banker GS, Anderson NR, editors. Tablets. Vol. 1. New York: Marcel Dekker; 1986. p. 211–237.
42. Parikh DM. Handbook of pharmaceutical granulation technology. Drugs and the pharmaceutical sciences. 2005;81.
43. Almeida-Naranjo CE, Guerrero VH, Villamar-Ayala CA. Emerging contaminants and their removal from aqueous media using conventional/non-conventional adsorbents: a glance at the relationship between materials, processes, and technologies. Water. 2023 Apr 21;15(8):1626.
44. Basciani S, Porcaro G. Counteracting side effects of combined oral contraceptives through the administration of specific micronutrients. European Review for Medical & Pharmacological Sciences. 2022 Jul 1;26(13).
45. Saha SK, Joshi A, Singh R, Dubey K. Review of industrially recognized polymers and manufacturing processes for amorphous solid dispersion-based formulations. Pharmaceutical Development and Technology. 2023 Aug 9;28(7):678-96.
46. Okur ME, Karantas ID, Okur NU, Siafaka PI. Hypertension in 2017: Update in treatment and pharmaceutical innovations. Current Pharmaceutical Design. 2017 Dec 1;23(44):6795-814.
47. Kalasz H, Antal I. Drug excipients. Current medicinal chemistry. 2006 Sep 1;13(21):2535-63.
48. Singh VK, Singh U, Mishra A, Chandra D, Sahu R. A Review on Mouth Dissolving Tablet Using Different Super Disintegrant. World J. Pharm. Res. 2014 Jul 13;3(7):755-91.
49. Lasekan A, Koganti S, et al. Use of disintegrants in tablets: A comprehensive review. Drug Dev Ind Pharm. 2014;40(2):183-191.
50. Qureshi MS, Zafar F, Ali H, Hameed K, Mallick N, Khan S, Baloch SA. Superdisintegrant On Disintegrant And Dissolution: A Review on Influence. The Professional Medical Journal. 2016 Oct 10;23(10):1167-70.
51. Panda S, Latha V, Pattnaik S, Maharana L, Prasad R. An update on various excipients employed for orodispersible tablets with a special focus on superdisintegrants. International Journal of Pharmaceutical and Clinical Research. 2015;7(6):440-9. Ghosh S, et al. Use of superdisintegrants in the development of fast-disintegrating tablets. Pharma Times. 2014;46(9):11–14.
52. Panda S, Latha V, Pattnaik S, Maharana L, Prasad R. An update on various excipients employed for orodispersible tablets with a special focus on superdisintegrants. International Journal of Pharmaceutical and Clinical Research. 2015;7(6):440-9.
53. Kar¹ M, Chourasiya Y, Maheshwari R. Current Developments in Excipient Science: Implication of Quantitative Selection of Each Excipient in. Basic Fundamentals of Drug Delivery. 2018 Nov 30:29. Martin A, Bustamante P, Chun A. Solid dispersions for enhanced solubility: A review. Drug Dev Ind Pharm. 1995;21(11):1259-1273.
54. Rashid M, Malik MY, Singh SK, Chaturvedi S, Gayen JR, Wahajuddin M. Bioavailability enhancement of poorly soluble drugs: the holy grail in pharma industry. Current Pharmaceutical Design. 2019 Mar 1;25(9):987-1020.Swain S, et al. Salt formation for enhancing the solubility of poorly soluble drugs. Int J Pharm Sci. 2011;10(3):44-49.
55. Singh V, Bansal K, Bhati H, Bajpai M. New insights into pharmaceutical nanocrystals for the improved topical delivery of therapeutics in various skin disorders. Current pharmaceutical biotechnology. 2024 Jul 1;25(9):1182-98. Ueda H, et al. Cyclodextrin complexes for solubility enhancement of lipophilic drugs. J Pharm Sci. 2010;99(2):925-931.
56. Peptu C, Humelnicu AC, Rotaru R, Fortuna ME, Patras X, Teodorescu M, Tamba BI, Harabagiu V. Chitosan?based drug delivery systems. Chitin and Chitosan: Properties and Applications. 2019 Dec 31:259-89.
57. Hwang J, et al. Fatty acids and surfactants in enhancing the intestinal permeability of poorly soluble drugs. J Pharm Sci. 2009;98(1):33-43.
58. Lau MH. Exploring new therapeutic properties from the encapsulation of pharmaceutical compounds within mesoporous silica particles (Doctoral dissertation, Macquarie University).
59. Debnath SK, Singh B, Agrawal N, Srivastava R. EPR-Selective Biodegradable Polymer-Based Nanoparticles for Modulating ROS in the Management of Cervical Cancer. InHandbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022 Sep 29 (pp. 2863-2889). Singapore: Springer Nature Singapore.Jain K, et al. Microneedle technology for enhanced drug permeability in oral formulations. Drug Dev Ind Pharm. 2015;41(9):1371-1378.
60. Patel R, Patel G. Preparation and Characterization of a Novel Optimum Modified Liquisolid Compact to Enhance the Dissolution Profile of Mifepristone. Dissolution Technologies. 2023 Nov 1;30(4):238-44.
61. Coimbra AT. Biological properties of aromatic plants used in folk medicine: a focus on the essential oil of Thymus zygis (Doctoral dissertation, Universidade da Beira Interior (Portugal)).
62. Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opinion on Drug Metabolism & Toxicology. 2020 Jan 2;16(1):59-78.
63. Omari DM, Akkam Y, Sallam A. Drug-excipient interactions: an overview on mechanisms and effects on drug stability and bioavailability. Annals of the Romanian Society for Cell Biology. 2021;25(4):8402-29.
64. Stewart SA, Domínguez-Robles J, Donnelly RF, Larrañeta E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers. 2018 Dec 12;10(12): 1379.Harper J, et al. Bioavailability of ethinyl estradiol in different formulation types. Int J Pharm. 2010;398(1-2):16-22.
65. Pahwa R, Gupta N. Superdisintegrants in the development of orally disintegrating tablets: a review. International journal of pharmaceutical sciences and research. 2011 Nov 1;2(11): 2767.Young L, et al. Solubilizing agents in oral contraceptive formulations. Int J Pharm. 2014;460(1-2):1-9.
66. Gomaa E, Faisal MM. Formulation and in-vitro evaluation of Propranolol Hcl mucoadhesive vaginal beads for contraceptive purposes. Zagazig Journal of Pharmaceutical Sciences. 2023 Dec 1;32(2):59-67.
67. Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE. Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using ph modifiers: a physiologically realistic mass transport analysis. Molecular Pharmaceutics. 2021 Aug 24;18(9):3326-41.
68. Yang X, Yang Y, Yu H, Zhou Y. Self-Assembled Polymers for Gastrointestinal Tract Targeted Delivery through the Oral Route: An Update. Polymers. 2023 Aug 25;15(17):3538.
69. Kalibala J, Pechere-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy—the example of hypertension: a mini review. Frontiers in pharmacology. 2020 May 6;11:564.Dimas F, et al. Impact of BMI on drug absorption in oral contraceptives. J Pharm Pharmacol. 2017;69(9):1290-1300.
70. Marchetti S, Schellens JH. Clinical relevance: drug–drug interactions, pharmacokinetics, pharmacodynamics, and toxicity. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2014 Aug 8:433-71.
71. Hulub? IP, Crecan-Suciu BD, P?unescu R, Miclu?ia IV. The link between sex hormones and depression over a woman's lifespan. Biomedical Reports. 2025 Feb 20;22(4):71.Patel RV, et al. Dissolution testing and bioavailability of oral contraceptives. J Pharm Sci. 2013;102(6):1894-1904.
72. Fadiran EO, Zhang L. Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women. InMedicines for women 2014 Dec 18 (pp. 41-68). Cham: Springer International Publishing.
73. Gupta MD. Unravelling the Role of Microbiome and Escherichia coli as a Trigger for Inflammatory Bowel Disease With a Particular Focus on Crohn's Disease (Doctoral dissertation, The Australian National University (Australia)).
74. Shah D, Patil M, National PCOS Working Group. Consensus statement on the use of oral contraceptive pills in polycystic ovarian syndrome women in India. Journal of human reproductive sciences. 2018 Apr 1;11(2):96-118.Dimas F, et al. Metabolism of progestins in oral contraceptives: The role of hepatic enzymes. Contraception. 2012;85(4):412-419.
75. Osi B, Khoder M, Al-Kinani AA, Alany RG. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent review. Pharmaceutical Development and Technology. 2022 Mar 16;27(3):341-56. Rowland M, et al. Drug interactions and their impact on oral contraceptive efficacy. J Clin Pharm. 2013;53(5):1232-1240.
76. Tassi A, Londero AP, Xholli A, Lanzolla G, Bertozzi S, Savelli L, Prefumo F, Cagnacci A. Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women. Pharmaceuticals. 2025 Jan 8;18(1):61.
77. Banjoko B. Environmental pharmacology–an overview. Pharmacol therapeut. 2014 Jul 2.
78. Mosorin ME. Metabolic effects of hormonal contraception in women with and without polycystic ovary syndrome.
79. Seghieri G, Franconi F, Campesi I. Why we need sex-gender medicine: The striking example of type 2 diabetes. Diabetology. 2022 Aug 11;3(3):460-9.
80. De Boer A, Van Hunsel F, Bast A. Adverse food–drug interactions. Regulatory Toxicology and Pharmacology. 2015 Dec 1;73(3):859-65.
81. Perkins MS. Investigating the mechanism of action of hormones used in hormone replacement therapy via estrogen receptor subtypes and the influence of the progesterone receptor (Doctoral dissertation, Stellenbosch: Stellenbosch University). Gupta S, et al. Effect of high-fat meals on the absorption of oral contraceptives. Clin Pharmacol Ther. 2015;97(2):101-107.
82. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clinical pharmacokinetics. 1997 Aug;33(2):103-21. Lippert J, et al. Food interactions with contraceptive drugs: Current perspectives. Ther Drug Monit. 2016;38(4):462-469.
83. Salole EG. Estradiol. InAnalytical profiles of drug substances 1986 Jan 1 (Vol. 15, pp. 283-318). Academic Press.
84. Robinson M. The pharmacodynamics and pharmacokinetics of proton pump inhibitors–overview and clinical implications. Alimentary pharmacology & therapeutics. 2004 Nov; 20:1-0.
85. Handelsman DJ. Androgen physiology, pharmacology, use and misuse. Endotext [Internet]. 2020 Oct 5.
86. Adetuyi BO, Olajide PA. Pharmacological and therapeutic potential of ginger in the management of neurodegenerative disorders.
87. VINOTH D. Professor & HOD.
88. Szidónia F. Mechanism of action and neuroprotective potential of estradiol and new non-genomic estrogen-like signaling activators (Doctoral dissertation, University of Pécs (Hungary)).
89. Sivasankaran S. A Study on the Use of Poly (L-Lactic Acid) in Long-Term Controlled Release of Levonorgestrel for Contraception. University of the Sciences in Philadelphia; 2021.
90. Akombaetwa N, Ilangala AB, Thom L, Memvanga PB, Witika BA, Buya AB. Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications. Pharmaceutics. 2023 Feb 15;15(2):656.
91. Osma?ek T, Froelich A, Jadach B, Tatarek A, Gadzi?ski P, Falana A, Grali?ska K, Ekert M, Puri V, Wroty?ska-Barczy?ska J, Michniak-Kohn B. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021 Jun 15;13(6):884.
92. Bhatia M, Devi S. Co-crystallization: a green approach for the solubility enhancement of poorly soluble drugs. CrystEngComm. 2024;26(3):293-311.
93. Than YM. Formulation development of extended and immediate release tablets using extrusion-based 3d printing technology.
94. Nippe S. Injectable drug delivery systems for steroids (Doctoral dissertation).
95. Bhattacharya P, Saha A, Basak S. Discovery of nano-piperolactam A: a nonsteroidal contraceptive lead acting through down-regulation of interleukins. Nanomedicine: Nanotechnology, Biology and Medicine. 2019 Jun 1; 18:347-58.
96. Walters KA, Lane ME. Dermal and transdermal drug delivery systems: an overview and recent advancements. Dermal Drug Delivery. 2020 Jan 21:1-60.
97. Osma?ek T, Froelich A, Jadach B, Tatarek A. Gadzi nski. Drug Deliv. 2016; 23:550-63.
98. Verdan M, Taveira I, Lima F, Abreu F, Nico D. Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). Expert Opinion on Therapeutic Patents. 2023 Mar 4;33(3):137-50.
99. Hameedat F, Hawamdeh S, Alnabulsi S, Zayed A. High performance liquid chromatography (HPLC) with fluorescence detection for quantification of steroids in clinical, pharmaceutical, and environmental samples: a review. Molecules. 2022 Mar 10;27(6):1807.
100. Hermans A, Abend AM, Kesisoglou F, Flanagan T, Cohen MJ, Diaz DA, Mao Y, Zhang L, Webster GK, Lin Y, Hahn DA. Approaches for establishing clinically relevant dissolution specifications for immediate release solid oral dosage forms. The AAPS journal. 2017 Nov; 19:1537-49.
101. Zhang Z. Application of Biorelevant Dissolution Method for Intrauterine Devices (Doctoral dissertation, University of Pittsburgh).
102. Shargel L, Kanfer I. Generic drug product development. DRUGS AND THE PHARMACEUTICAL SCIENCES. 2014 Oct 31; 204:204.
103. Jange CG, Wassgren CR, Ambrose K. The significance of tablet internal structure on disintegration and dissolution of immediate-release formulas: A review. Powders. 2023 Feb 17;2(1):99-123.
104. Singh GR. Design, Development and Evaluation of Controlled-Release Formulation of Freely Water-Soluble Drugs (Doctoral dissertation, Institute of Pharmacy, Nirma University, A'bad).
105. Stone J, Mitrofanis J, Johnstone DM, Falsini B, Bisti S, Adam P, Nuevo AB, George-Weinstein M, Mason R, Eells J. Acquired resilience: an evolved system of tissue protection in mammals. Dose-Response. 2018 Dec 27;16(4):1559325818803428.
106. Osma?ek T, Froelich A, Jadach B, Tatarek A, Gadzi?ski P, Falana A, Grali?ska K, Ekert M, Puri V, Wroty?ska-Barczy?ska J, Michniak-Kohn B. Recent advances in polymer-based vaginal drug delivery systems. Pharmaceutics. 2021 Jun 15;13(6):884.
107. Guideline IH. Bioequivalence for immediate-release solid oral dosage forms M13A. Draft version endorsed on. 2022 Dec 20;20.
108. Zhao JZ, Lin JJ, Yang HY, Zhang W, Huang XF, Huang YP. Effects of oral contraceptives and metformin on the outcome of in vitro maturation in infertile women with polycystic ovary syndrome. Journal of Women's Health. 2010 Feb 1;19(2):261-5.
109. Zheng X, Guo T, Wu F, Shen L, Lin X. Sustained-Release Drug Delivery Systems of Chinese Medicines. Novel Drug Delivery Systems for Chinese Medicines. 2021:49-76.
110. Berry C, Morrow A, Abraham G, Hoole S, Greenwood J, Arnold J, Shanmuganathan M, Ferreira V, Rakhit R, Galasko G, Sinha A. Precision Pharmacotherapy With Zibotentan in Microvascular Angina: a randomized, placebo-controlled, cross-over trial.
111. Khobragade DS, Agrawal SS, Potbhare MS. Pharmacokinetic Considerations for Controlled-release Dosage Forms. Novel Drug Delivery Systems (Part 1). 2024 Dec 5:39.
112. Song J, Xu Z, Xie L, Shen J. Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes. Pharmaceutics. 2025 Feb 14;17(2):256.
113. Fernandes EA, Oudtshoorn JV, Tam A, González LC, Aurela EG, Potthast H, Mettke K, Kuribayashi R, Shimojo K, Kasuga M, Morales L. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities. Journal of Pharmacy & Pharmaceutical Sciences. 2024 Mar 21; 27:12398.
114. Diehl DL, Tierney WM, Adler DG, Conway JD, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Pedrosa MC. The role of the US Food and Drug Administration in device evaluation and monitoring. Gastrointestinal Endoscopy. 2010 Jul 1;72(1):5-10.
115. Durán CE, Riera-Arnau J, Abtahi S, Pajouheshnia R, Hoxhaj V, Gamba M, Alsina E, Martin-Perez M, Garcia-Poza P, Llorente-Garcia A, Gonzalez-Bermejo D. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis. Frontiers in Pharmacology. 2023 Aug 17; 14:1207976.
116. Sardella M, Costanzo L. The 7th European Pharmacovigilance Congress: speaker abstracts.
117. Marathe PA, Kamat SK, Tripathi RK, Raut SB, Khatri NP. Over-the-counter medicines: Global perspective and Indian scenario. Journal of postgraduate medicine. 2020 Jan 1;66(1):28-34.